Industry
Biotechnology
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Insights
March 26, 2024 | 9:32 pm
Portfolio Pulse from Benzinga Insights
March 08, 2024 | 9:31 pm
Portfolio Pulse from Avi Kapoor
January 17, 2024 | 1:18 pm
Portfolio Pulse from Benzinga Insights
January 16, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Insights
January 12, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Insights
January 12, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Insights
January 10, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Insights
January 02, 2024 | 1:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.